Aktienanalyse zu Fractyl Health Inc (GUTS)GUTSFractyl Health Inc

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Fractyl Health Inc (GUTS) is currently not a good buy due to its very low current price of $0.93, which is significantly below its 52-week high of $29.34, indicating a severe decline of 96.56% year-to-date. The RSI is at 25.036, suggesting the stock is oversold, but the lack of revenue and the negative earnings per share (EPS) of -1.5900 for the upcoming earnings report raises concerns. The main risk is the company's substantial net income loss of -25,538,000 USD in Q2 2026, which could further impact its financial stability.